Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Anastrozole and Fulvestrant in Patients With ER Positive, HER2 Negative, Operable Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed infiltrating breast adenocarcinoma~  * Large, operable tumor~ * Stage T2 (≥ 3 cm) or T3-T4 (excluding inflammatory disease), N0-N3, M0 disease~    * No bilateral inflammatory breast tumors (T4d \[PEV-2 or PEV-3\])~ * Elston-Ellis grade I or II and mitotic index 1 or 2 (if \< 65 years of age)~* At least 1 embedded and 1 frozen biopsy sample available~* No multifocal or multicentric tumors for which breast conservation cannot be envisaged~* No ErbB2-overexpressing tumors (HER2 3+ by IHC OR HER2 2+ by IHC and FISH positive)~* Hormone receptor status:~  * Estrogen receptor and/or progesterone receptor positive tumor (\> 10%) as assessed by IHC~PATIENT CHARACTERISTICS:~* Female~* Postmenopausal~* ECOG performance status 0-2~* ANC ≥ 2,000/mm³~* Platelet count ≥ 100,000/mm³~* Hemoglobin ≥ 10 g/dL~* Creatinine ≤ 1.5 times upper limit of normal (ULN)~* Total bilirubin ≤ 1.25 times ULN~* AST and ALT ≤ 1.5 times ULN~* Alkaline phosphatase ≤ 2.5 times ULN~* No other cancer within the past 10 years, except basal cell skin cancer or previously treated carcinoma in situ of the cervix~* No uncontrolled cardiac pathology, including any of the following:~  * Angina pectoris~ * Congestive cardiac insufficiency~ * Myocardial infarction within the past 3 months~* No known history of hemorrhagic diathesis~* No known allergy to the study drugs or their excipients~* No congenital galactosemia, glucose malabsorption syndrome, or lactase deficiency~* No chronic somatic or psychiatric illness with pejorative prognosis~* No geographical, social, or psychiatric condition that would preclude study compliance and follow-up schedule~* No individual deprived of liberty or placed under the authority of a tutor~PRIOR CONCURRENT THERAPY:~* No prior chemotherapy, hormonal therapy, or any targeted treatment for the breast tumor~* At least 2 weeks since prior hormone replacement therapy for menopause~* No concurrent long-term anticoagulation treatment~* No concurrent participation on another therapeutic trial involving an experimental molecule

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): Anastrozole
- Arm B (Type: EXPERIMENTAL): Fulvestrant

Based on this trial design, predict the completion outcome and termination type (if applicable).